Journal Mobile Options
Table of Contents
Vol. 70, No. 4, 2010
Issue release date: November 2010
Gynecol Obstet Invest 2010;70:306–321

Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness

Donders G.G.G. · Bellen G. · Mendling W.
aFemicare, Clinical Research for Women, Tienen, and Departments of Obstetrics and Gynaecology, bUniversity Hospital Gasthuisberg Leuven, Leuven, cGeneral Hospital Heilig Hart, Tienen, and dUniversity Hospital Citadelle Liège, Liège, Belgium; eKlinik für Gynäkologie und Geburtsmedizin, Vivantes-Klinika im Friedrichshain und am Urban, Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate ‘don’t do’s’, unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Odds FC, Arai T, Disalvo AF, Evans EG, Hay RJ, Randhawa HS, Rinaldi MG, Walsh TJ: Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992;30:1–10.
  2. Reed BD, Zazove P, Pierson CL, Gorenflo DW, Horrocks J: Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003;12:979–989.
  3. Spinillo A, Carratta L, Pizzoli G, Lombardi G, Cavanna C, Michelone G, Guaschino S: Recurrent vaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med 1992;37:343–347.
  4. Bisschop MP, Merkus JM, Scheygrond H, Van CJ: Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986;93:79–81.
  5. Fong IW: The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992;68:174–176.
  6. Shihadeh AS, Nawafleh AN: The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000;21:1065–1067.
  7. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK: Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185:380–385.
  8. Sobel JD: Vulvovaginitis: when Candida becomes a problem. Dermatol Clin 1998;16:763–768, xii.
  9. El-Din SS, Reynolds MT, Ashbee HR, Barton RC, Evans EG: An investigation into the pathogenesis of vulvo-vaginal candidosis. Sex Transm Infect 2001;77:179–183.
  10. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereecken A, Van EJ: Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008;199:613–619.
  11. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C III, Horowitz B, Von TJ, Edwards L, Panzer H, Chu TC: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876–883.
  12. Hay P, Czeizel AE: Asymptomatic Trichomonas and Candida colonization and pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:403–409.
  13. Pirotta MV, Garland SM: Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006;44:3213–3217.
  14. Donders GG, Larsson PG, Platz-Christensen JJ, Hallén A, van der Meijden W, Wölner-Hanssen P: Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur J Obstet Gynecol Reprod Biol 2009;145:109–112.
  15. Sobel JD: Vulvovaginal candidosis. Lancet 2007;369:1961–1971.
  16. Emmerson J, Gunputrao A, Hawkswell J, Dexter A, Sykes R, Searle S, Cross A, Nathan PM: Sampling for vaginal candidosis: how good is it? Int J STD AIDS 1994;5:356–358.
  17. Passos MR, Varella RQ, Barreto NA, Garcia ML, Giraldo PC: Accuracy of a self-collection kit for the microbiological study of the vaginal content. Braz J Infect Dis 2007;11:249–253.
  18. van de Wijgert J, Altini L, Jones H, de Kock A, Young T, Williamson AL, Hoosen A, Coetzee N: Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. Sex Transm Dis 2006;33:516–523.
  19. Weissenbacher T, Witkin SS, Ledger WJ, Tolbert V, Gingelmaier A, Scholz C, Weissenbacher ER, Friese K, Mylonas I: Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009;279:125–129.
  20. Lowe NK, Neal JL, Ryan-Wenger NA: Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol 2009;113:89–95.
  21. Nowakowska D, Gaj Z, Sobala W, Wilczynski J: Evaluation of susceptibility to antifungal agents of fungal strains isolated from pregnant women with diabetes and healthy pregnant women. Ginekol Pol 2009;80:274–279.

    External Resources

  22. Looi CY, D’ Silva EC, Seow HF, Rosli R, Ng KP, Chong PP: Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients. FEMS Microbiol Lett 2005;249:283–289.
  23. Cernicka J, Subik J: Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006;27:403–408.
  24. Pitsouni E, Iavazzo C, Falagas ME: Itraconazole vs. fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2008;198:153–160.
  25. Owen MK, Clenney TL: Management of vaginitis. Am Fam Physician 2004;70:2125–2132.
  26. Ries AJ: Treatment of vaginal infections: candidiasis, bacterial vaginosis, and trichomoniasis. J Am Pharm Assoc (Wash) 1997;NS37:563–569.
  27. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A: Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007;CD002845.
  28. De Seta F, Schmidt M, Vu B, Essmann M, Larsen B: Antifungal mechanisms supporting boric acid therapy of Candida vaginitis. J Antimicrob Chemother 2009;63:325–336.
  29. Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297–1300.
  30. White DJ, Johnson EM, Warnock DW: Management of persistent vulvo-vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993;69:112–114.
  31. Stein GE, Mummaw NL, Schooley SL: Prevention of recurrent vaginal candidiasis with weekly terconazole cream. Ann Pharmacother 1996;30:1080–1083.
  32. Balsdon MJ, Tobin JM: Recurrent vaginal candidosis: prospective study of effectiveness of maintenance miconazole treatment. Genitourin Med 1988;64:124–127.
  33. Sobel JD: Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315:1455–1458.
  34. Meyer H, Goettlicher S, Mendling W: Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006;49:202–209.
  35. Ehrstrom SM, Kornfeld D, Thuresson J, Rylander E: Signs of chronic stress in women with recurrent Candida vulvovaginitis. Am J Obstet Gynecol 2005;193:1376–1381.
  36. Fidel PL Jr: Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005;18:107–111.
  37. Barousse MM, Van Der Pol BJ, Fortenberry D, Orr D, Fidel PL Jr: Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents. Sex Transm Infect 2004;80:48–53.
  38. Fidel PL Jr, Barousse M, Lounev V, Espinosa T, Chesson RR, Dunlap K: Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle. Med Mycol 2003;41:97–109.

    External Resources

  39. Fidel PL Jr, Ginsburg KA, Cutright JL, Wolf NA, Leaman D, Dunlap K, Sobel JD: Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997;176:728–739.
  40. Neves NA, Carvalho LP, Lopes AC, Cruz A, Carvalho EM: Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole. J Low Genit Tract Dis 2005;9:167–170.
  41. Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM, Dussourd DL: Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989;7:337–340.
  42. Liu F, Liao Q, Liu Z: Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006;92:43–47.
  43. IP W, Lau YL: Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2005;190:632–640.

    External Resources

  44. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR: Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006;193:1589–1597.
  45. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS: Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003;37:733–737.
  46. Donders GG, Babula O, Bellen G, Linhares IM, Witkin SS: Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008;115:1225–1231.
  47. Giraldo PC, Babula O, Goncalves AK, Linhares IM, Amaral RL, Ledger WJ, Witkin SS: Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007;109:1123–1128.
  48. Mardh PA, Wagstrom J, Landgren M, Holmen J: Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription. 2. Factors that may have influenced the marked changes in sales volumes during the 1990s. Infect Dis Obstet Gynecol 2004;12:99–108.
  49. Mardh PA, Wagstrom J, Landgren M, Holmen J: Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription. I. Analyses of a unique database. Infect Dis Obstet Gynecol 2004;12:91–97.
  50. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ: Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002;187:569–574.
  51. Cernicka J, Subik J: Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006;27:403–408.
  52. Rahman KM, Chowdhury TA, Nahar N, Huq JA: General yeast infection in Bangladeshi women using contraceptives. Bangladesh Med Res Counc Bull 1984;10:65–70.
  53. Otero L, Palacio V, Carreno F, Mendez FJ, Vazquez F: Vulvovaginal candidiasis in female sex workers. Int J STD AIDS 1998;9:526–530.
  54. Omar AA: Gram stain versus culture in the diagnosis of vulvovaginal candidiasis. East Mediterr Health J 2001;7:925–934.
  55. Ozcan SK, Budak F, Yucesoy G, Susever S, Willke A: Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. APMIS 2006;114:139–145.
  56. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W: A 5-year (2000–2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006;49:471–475.
  57. Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Mordechai E, Gygax SE: Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008;46:1501–1503.
  58. al-Rawi N, Kavanagh K: Characterisation of yeasts implicated in vulvovaginal candidosis in Irish women. Br J Biomed Sci 1999;56:99–104.
  59. Erdem H, Cetin M, Timuroglu T, Cetin A, Yanar O, Pahsa A: Identification of yeasts in public hospital primary care patients with or without clinical vaginitis. Aust NZ J Obstet Gynaecol 2003;43:312–316.
  60. Geiger AM, Foxman B, Sobel JD: Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med 1995;71:304–307.
  61. Sobel JD: Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998;41(suppl 2):18–22.
  62. Enweani IB, Ogbonna CI, Kozak W: The incidence of candidiasis amongst the asymptomatic female students of the University of Jos, Nigeria. Mycopathologia 1987;99:135–141.
  63. Okungbowa FI, Isikhuemhen OS, Dede AP: The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol 2003;20:60–63.

    External Resources

  64. de Leon EM, Jacober SJ, Sobel JD, Foxman B: Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002;2:1.
  65. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehrlich I, DeHovitz J: Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women.
  66. Mendling W: Torulopsis in gynecology. Geburtshilfe Frauenheilkd 1984;44:583–586; Obstet Gynecol 1997;90:252–256.
  67. Dhingra S, Roseblade CK: Boric acid for refractory Candida glabrata vaginitis. J Obstet Gynaecol 2006;26:584.
  68. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V, Kochupillai N: Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007;30:312–317.
  69. Mendling W, Pinto De Andrade M, Gutschmidt J, Gantenberg R, Presber W, Schonian G: Strain specificity of yeasts isolated from different locations of women suffering from vaginal candidosis, and their partners. Mycoses 2000;43:387–392.
  70. Lockhart SR, Reed BD, Pierson CL, Soll DR: Most frequent scenario for recurrent Candida vaginitis is strain maintenance with ‘substrain shuffling’: demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol 1996;34:767–777.
  71. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK: Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 2005;106:105–114.
  72. Donders GG, Mertens I, Bellen G, Pelckmans S: Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses 2009, electronically published ahead of print: MYC1754 [pii]; 10.1111/j.1439–0507.2009. 01754.x [doi]
  73. Gertig DM, Kapiga SH, Shao JF, Hunter DJ: Risk factors for sexually transmitted diseases among women attending family planning clinics in Dar-es-Salaam, Tanzania. Genitourin Med 1997;73:39–43.
  74. Geiger AM, Foxman B: Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182–187.
  75. Ginter G, Soyer HP, Rieger E: Vaginal yeast colonization and promiscuity: a study of 197 prostitutes. Mycoses 1992;35:177–180.
  76. Fong IW: The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992;68:174–176.
  77. Shihadeh AS, Nawafleh AN: The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000;21:1065–1067.
  78. Wilton L, Kollarova M, Heeley E, Shakir S: Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003;26:589–597.
  79. Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A, Monaco A: The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995;51:293–297.
  80. Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S: Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993;81:721–727.
  81. Daus AD, Hafez ES: Candida albicans in women. Nurs Res 1975;24:430–433.
  82. Rohatiner JJ, Grimble A: Genital candidasis and oral contraceptives. J Obstet Gynaecol Br Commonw 1970;77:1013–1015.
  83. Morris CA: Influence of oral contraceptives on the presence and persistence of Candida albicans and beta-haemolytic streptococci in the vagina. J Clin Pathol 1969;22:488–491.
  84. Ceruti M, Canestrelli M, Condemi V, Piantelli G, De Paolis P, Amone F, Tovagliari D: Methods of contraception and rates of genital infections. Clin Exp Obstet Gynecol 1994;21:119–123.
  85. Hart G: Factors associated with trichomoniasis, candidiasis and bacterial vaginosis. Int J STD AIDS 1993;4:21–25.
  86. Birnbaum H, Kraussold E: Incidence of the Blastomyces and Trichomonad infections during the use of hormonal and intrauterine contraception. Zentralbl Gynäkol 1975;97:1636–1640.
  87. Tarry W, Fisher M, Shen S, Mawhinney M: Candida albicans: the estrogen target for vaginal colonization. J Surg Res 2005;129:278–282.
  88. Fosch S, Fogolin N, Azzaroni E, Pairetti N, Dana L, Minacori H, Tita I, Redona M, Gribaudo G: Vulvovaginitis: correlation with predisposing factors, clinical manifestations and microbiological studies. Rev Argent Microbiol 2006;38:202–205.
  89. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL: Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004;104:926–930.
  90. Veres S, Miller L, Burington B: A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555–563.
  91. Parewijck W, Claeys G, Thiery M, van Kets H: Candidiasis in women fitted with an intrauterine contraceptive device. Br J Obstet Gynaecol 1988;95:408–410.
  92. Hodoglugil NN, Aslan D, Bertan M: Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 2000;61:359–364.
  93. Karaer A, Boylu M, Avsar AF: Vaginitis in Turkish women: symptoms, epidemiologic-microbiologic association. Eur J Obstet Gynecol Reprod Biol 2005;121:211–215.
  94. de Oliveira JM, Cruz AS, Fonseca AF, Vaz CP, Rodrigues A, Aurea F, Maia J, Sousa JA: Prevalence of Candida albicans in vaginal fluid of asymptomatic Portuguese women. J Reprod Med 1993;38:41–42.
  95. Horowitz BJ, Edelstein SW, Lippman L: Sugar chromatography studies in recurrent Candida vulvovaginitis. J Reprod Med 1984;29:441–443.
  96. Donders GG, Berger J, Heuninckx H, Bellen C: Vaginal flora changes on Pap smears after insertion of intrauterine levonorgestrel- releasing device (Mirena®). Contraception 2010.
  97. Reed BD, Slattery ML, French TK: The association between dietary intake and reported history of Candida vulvovaginitis. J Fam Pract 1989;29:509–515.
  98. Donders GG, Prenen H, Verbeke G, Reybrouck R: Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002;187:989–993.
  99. Donders GG: Lower genital tract infections in diabetic women. Curr Infect Dis Rep 2002;4:536–539.
  100. Ehrstrom S, Yu A, Rylander E: Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol 2006;108:1432–1437.
  101. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G: The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005;112:234–240.
  102. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT: Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353–357.
  103. Patel DA, Gillespie B, Sobel JD, Leaman D, Nyirjesy P, Weitz MV, Foxman B: Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004;190:644–653.
  104. Edman J, Sobel JD, Taylor ML: Zinc status in women with recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1986;155:1082–1085.
  105. Jobst D, Kraft K: Candida species in stool, symptoms and complaints in general practice – a cross-sectional study of 308 outpatients. Mycoses 2006;49:415–420.
  106. Raska M, Belakova J, Horynova M, Krupka M, Novotny J, Sebestova M, Weigl E: Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008;46:411–420.
  107. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A: A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597–606.
  108. Mendling W, Koldovsky U: Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses. Infect Dis Obstet Gynecol 1996;4:225–231.
  109. Mendling W, Koldovsky U: Immunological investigations in vaginal mycoses. Mycoses 1996;39:177–183.
  110. Altamura M, Casale D, Pepe M, Tafaro A: Immune responses to fungal infections and therapeutic implications. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:189–197.
  111. Cardenas-Freytag L, Steele C, Wormley FL Jr, Cheng E, Clements JD, Fidel PL Jr: Partial protection against experimental vaginal candidiasis after mucosal vaccination with heat-killed Candida albicans and the mucosal adjuvant LT(R192G). Med Mycol 2002;40:291–299.
  112. De Bernardis F, Boccanera M, Adriani D, Girolamo A, Cassone A: Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 2002;70:2725–2729.
  113. Han Y, Morrison RP, Cutler JE: A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998;66:5771–5776.
  114. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F: Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619–2624.
  115. Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM, Dussourd DL: Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989;7:337–340.
  116. Waldman RH, Cruz JM, Rowe DS: Intravaginal immunization of humans with Candida albicans. J Immunol 1972;109:662–664.
  117. Rigg D, Miller MM, Metzger WJ: Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990;162:332–336.
  118. Farage M, Bramante M, Otaka Y, Sobel J: Do panty liners promote vulvovaginal candidiasis or urinary tract infections? A review of the scientific evidence. Eur J Obstet Gynecol Reprod Biol 2007;132:8–19.
  119. Elegbe IA, Botu M: A preliminary study on dressing patterns and incidence of candidiasis. Am J Public Health 1982;72:176–177.
  120. Mardh PA, Novikova N, Stukalova E: Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis. BJOG 2003;110:934–937.
  121. Reed BD, Ford K, Wirawan DN: The Bali STD/AIDS study: association between vaginal hygiene practices and STDs among sex workers. Sex Transm Infect 2001;77:46–52.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50